enGene (NASDAQ:ENGN) Coverage Initiated at Jefferies Financial Group

Research analysts at Jefferies Financial Group initiated coverage on shares of enGene (NASDAQ:ENGN) in a report released on Friday, Marketbeat.com reports. The brokerage set a “buy” rating and a $28.00 price target on the stock. Jefferies Financial Group’s price objective would suggest a potential upside of 193.81% from the stock’s previous close.

A number of other research analysts also recently issued reports on the company. UBS Group upped their price target on enGene from $4.00 to $10.00 and gave the company a “neutral” rating in a report on Wednesday, November 12th. Morgan Stanley upped their target price on shares of enGene from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Wednesday, November 12th. Oppenheimer reiterated an “outperform” rating and issued a $33.00 price target (up from $30.00) on shares of enGene in a research note on Wednesday, November 12th. Citigroup restated a “market outperform” rating on shares of enGene in a research report on Monday, January 5th. Finally, Raymond James Financial raised shares of enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 target price for the company in a research report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $23.00.

enGene Trading Down 7.2%

Shares of NASDAQ ENGN opened at $9.53 on Friday. The firm’s 50 day moving average price is $8.89 and its 200-day moving average price is $6.98. enGene has a 52-week low of $2.65 and a 52-week high of $12.25. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.30 and a current ratio of 6.30. The company has a market cap of $638.41 million, a PE ratio of -4.16 and a beta of -0.29.

enGene (NASDAQ:ENGN) last announced its quarterly earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.18). On average, equities research analysts expect that enGene will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On enGene

Several institutional investors and hedge funds have recently bought and sold shares of ENGN. Braidwell LP bought a new stake in enGene during the third quarter valued at about $15,479,000. Affinity Asset Advisors LLC bought a new position in shares of enGene during the 2nd quarter valued at approximately $280,000. Citadel Advisors LLC grew its stake in shares of enGene by 153.3% during the 3rd quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock valued at $399,000 after acquiring an additional 35,327 shares during the period. Millennium Management LLC increased its holdings in enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after acquiring an additional 7,472 shares in the last quarter. Finally, Hudson Bay Capital Management LP bought a new stake in enGene during the 3rd quarter worth approximately $76,000. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

enGene Company Profile

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.